MUMBAI, India, July 5 -- Intellectual Property India has published a patent application (202517059830 A) filed by Institut National De La Sante Et De La Recherche Medicale; Centre National De La Recherche Scientifique; Universite De Montpellier; Ecole Nationale Superieure De Chimie De Montpellier; and Centre Hospitalier Universitaire De Montpellier, Paris, on June 23, for '4(rs)-4-f4-neuroprostane derivatives (4-f4t-neurop) and their use in treating ventilator induced diaphragmatic dysfunction and other diseases.'
Inventor(s) include Lacampagne, Alain; Le Guennec, Jean-Yves; Durand, Thierry; Bultel-Ponce, Valerie; Roy, Jerome; Matecki, Stephan; Dridi, Haikel; Guy, Alexandre; Oger, Camille; and Galano, Jean-Marie.
The application for the patent was published on July 4, under issue no. 27/2025.
According to the abstract released by the Intellectual Property India: "Respiratory muscle contractile inactivity during mechanical ventilation (MV) induces diaphragm muscle weakness, a condition referred to as ventilator-induced diaphragm dysfunction (VIDD). Among the different hypothesis to explain VIDD, one involves the remodeling of the sarcoplasmic reticulum (SR) calcium release channel/ryanodine receptors (RyR1) in the diaphragm as a proximal mechanism of VIDD. The inventors have developed novel derivatives which prevent with a high efficiency VIDD both in a murine and porcine model of VIDD. This effect is associated with a normalization of RyR function. The present invention thus relates to novel compounds and their use in the treatment of diseases associated with Ryanodine Receptor (RyR) dysfunction."
The patent application was internationally filed on Nov. 23, 2023, under International application No.PCT/EP2023/082873.
Disclaimer: Curated by HT Syndication.
